SION logo

SIONNA THERAPEUTICS INC

SIONNASDAQ
πŸ† #3662 by market capUS Equity
$4.01β–Ό $0.03 (βˆ’0.74%)
Market closed Β· at close
πŸ””
Track SION
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.7%
7dβ–² 11.5%
14dβ–² 2.6%
30dβ–Ό 23.6%
ytdβ–Ό 90.3%
1yβ–Ό 89.4%
🏦Market Cap
$181M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$3.98 – $4.16
52-Week Range
$3.55 – $54.97
Volume (shares)
34,506
Avg Volume (shares)
β€”
Shares Outstanding
45.2M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-2.17
Dividend Yield
β€”
Dilution (1yr)
βˆ’9.4%
SION logo

SIONNA THERAPEUTICS INC

SION
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$89Mβ–² +26.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$67Mβ–² +26.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.0Mβ–Ό βˆ’9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50Mβ–² +$22M YoY
StockOtter Β· stockotter.space

About SIONNA THERAPEUTICS INC

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.